Ongoing projects
Consumption pattern and Sd. Cannabis-tobacco withdrawal in people with tr. for cannabis use
Cannabis is the most widely consumed illegal drug in Spain. In recent years, a notable increase in the number of visits to drug addiction services for treatment of its use has been detected. The majority of cannabis users are also tobacco users and the dual cannabis-tobacco consumption pattern is increasingly common in Western countries. However, the characterization of this consumption pattern and the associated withdrawal symptoms is poorly identified, among other reasons due to the complexity of the consumption routes and the multitude of products used to consume both cannabis and tobacco, which make it difficult to describe the distinctive withdrawal symptoms between both substances.
Characterize the pattern of dual cannabis-tobacco consumption (exclusive cannabis consumption, concurrent and/or simultaneous with tobacco products), in people who are starting a process of abandoning or reducing cannabis.
Describe the withdrawal symptoms of both substances during the quitting process, taking into account the type of consumption and characteristics of the people (sex, age, etc.).
Identify changes in the pattern of cannabis-tobacco consumption and the likelihood of abstinence in people who initiate treatment for cannabis use according to their individual and clinical characteristics.
Sequential mixed methods study.
Phase I: Qualitative study through homogeneous discussion groups that will allow the development of a gamified mobile application.
Phase II: Prospective longitudinal study in which people with this disorder treated in Drug Addiction Care and Monitoring Centers in the province of Barcelona will be followed during 2021-2022.
Phase III: Qualitative study using homogeneous discussion groups to explore the experiences of participants during the process of quitting cannabis and/or tobacco.
3 years (January 2021 – 2024)
€85,742.6 for the National Drug Plan
Cristina Martínez, Catalan Institute of Oncology (IP)
Esteve Fernández, Catalan Institute of Oncology
Marcela Fu, Catalan Institute of Oncology
Montse Ballbè, Catalan Institute of Oncology
Ariadna Feliu, Catalan Institute of Oncology
Marta Enríquez, Catalan Institute of Oncology
Yolanda Castellano, Catalan Institute of Oncology
Marga Pla, University of Barcelona
Petia Radeva, University of Barcelona
Elena Maestre, University of Barcelona
Carmen Cabezas, Public Health Agency of Catalonia
Joan Colom, Public Health Agency of Catalonia
Josep Maria Suelves, Public Health Agency of Catalonia
Silvia Mondon, Clinical and Provincial Hospital of Barcelona
Pablo Barrio, Clinical and Provincial Hospital of Barcelona
Magalí Andreu, Clinical and Provincial Hospital of Barcelona
Antonia Raich, Althaia Foundation
Jordi Bernabeu, Althaia Foundation
Jordi Vilaplana, University of Lleida
Ana Andrés, Ramon Llull University
Xavier Roca, Hospital de la Santa Creu i Sant Pau
Joseph Guydish, University of California San Francisco